UBS Says Moderna (MRNA) Management Sounds Confident Following Fireside Chat Ahead of Potential Ph3 CMV Data
Tweet Send to a Friend
UBS analyst Eliana Merle reiterated a Buy rating and $143.00 price target on Moderna (NASDAQ: MRNA).The analyst comments "Latent virus ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
